8-K: Harrow Inc. Announces Record Fourth-Quarter and Year-End 2024 Financial Results, Revenue Surges

Harrow Inc. reports record Q4 and full-year 2024 revenues, driven by strong performance of key products like IHEEZO and VEVYE, and issues optimistic 2025 revenue guidance.

Summary

• Harrow Inc. announced its financial results for the fourth quarter and year ended December 31, 2024.
• The company reported record revenues of $66.8 million for Q4 2024, an 84% increase compared to Q4 2023.
• Full-year 2024 revenues reached $199.6 million, a 53% increase over 2023.
• GAAP net income for Q4 2024 was $6.8 million, while the GAAP net loss for the full year was $(17.5) million.
• Adjusted EBITDA for Q4 2024 was $22.5 million, resulting in Adjusted EBITDA of $40.3 million for the full year.
• IHEEZO unit demand and VEVYE prescriptions each increased over 40% from Q3 to Q4 2024.
• The company expects its momentum to continue in 2025, with revenue guidance of more than $280 million, representing over 40% annual revenue growth.
• Harrow launched the VEVYE Access for All program to improve patient access and affordability.
• TRIESENCE received transitional pass-through approval, significantly increasing its addressable market.
• The company is developing a next-generation version of TRIESENCE, with an NDA submission planned before the end of 2027.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record revenues, strong product growth, and optimistic guidance. While there are some challenges and risks mentioned, the overall tone is confident and forward-looking.

Positives

• Record revenues achieved in Q4 2024 and full-year 2024.
• Significant growth in IHEEZO unit demand and VEVYE prescriptions.
• Successful meeting of the annual leverage ratio term under the senior secured loan agreement, avoiding the need to issue warrants.
• Launch of the VEVYE Access for All program to improve patient access.
• TRIESENCE received transitional pass-through approval, expanding its market.
• Development of a next-generation version of TRIESENCE underway.
• Strong performance of ImprimisRx, contributing record quarterly revenues.
• Jury verdict award of $34.9 million in the case of ImprimisRx, LLC v. OSRX, Inc.

Negatives

• GAAP net loss of $(17.5) million for the full year 2024, despite a net income of $6.8 million in Q4 2024.
• Cash and cash equivalents decreased from $74.1 million in 2023 to $47.2 million in 2024.
• Extended payment terms to a large distributor negatively impacted cash flows from operations by approximately $17.8 million in Q4 2024.

Risks

• Potential impact of tariffs on the business, although the company does not anticipate a noticeable impact.
• Inaccuracy of VEVYE prescription data from third-party aggregators starting in Q2 2025.
• Risks related to refinancing or repaying debt obligations.
• Dependence on key products like IHEEZO and VEVYE for revenue growth.
• Competition from other pharmaceutical companies in the ophthalmic market.
• Uncertainty regarding the outcome of future acquisitions and in-licensing opportunities.

Future Outlook

Harrow expects revenue to exceed $280 million in 2025, representing over 40% growth, with higher-margin branded business driving the majority of the growth.

Management Comments

• Mark L. Baum, CEO of Harrow, stated that the company's stellar fourth-quarter performance marked the end of a monumental year.
• Baum expects the company's momentum to continue in 2025, particularly in the second half, as the VEVYE Access for All program gains traction.
• Baum added that the company continues to review new ways to better serve its customers and leverage its commercial infrastructure.
• Baum is confident in the remainder of 2025, as demonstrated by the 2025 revenue guidance of more than $280 million.

Industry Context

Harrow's focus on ophthalmic pharmaceuticals aligns with the growing demand for innovative eye care solutions. The company's strategic initiatives, such as the VEVYE Access for All program and the development of a next-generation TRIESENCE, position it to compete effectively in the market.

Comparison to Industry Standards

• While specific competitor data isn't provided, the report highlights Harrow's growth in key products like IHEEZO and VEVYE, suggesting a competitive position in the ophthalmic market.
• The VEVYE Access for All program is described as the most generous market access program in the U.S. prescription dry eye market, indicating a potentially differentiated approach compared to competitors.
• The company's focus on branded products and strategic acquisitions aligns with industry trends of pharmaceutical companies seeking to expand their portfolios and market reach.

Legal Proceedings

• The company announced that it had received a $34.9 million jury verdict award in the case of ImprimisRx, LLC v. OSRX, Inc.

Stakeholder Impact

• Shareholders: Positive impact due to increased revenue, profitability, and future growth prospects.
• Employees: Positive impact due to company growth and success.
• Customers: Positive impact due to improved access to ophthalmic pharmaceutical products.
• Patients: Positive impact due to improved access to VEVYE through the VEVYE Access for All program.

Next Steps

• Continue to focus on revenue growth from increased IHEEZO unit demand.
• Improve patient access to VEVYE and significantly grow U.S. dry eye disease (DED) market share.
• Make TRIESENCE the injectable steroid of choice for U.S. ophthalmologists.
• Leverage the portfolio of products and commercial organization throughout the enterprise.
• Continue discussions with lenders and potential partners to review options for refinancing or repaying debt obligations.
• Submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for the next-generation version of TRIESENCE before the end of 2027.

Key Dates

Keywords

Harrow, IHEEZO, VEVYE, TRIESENCE, Ophthalmic, Pharmaceutical, Revenue, EBITDA, Financial Results, Dry Eye Disease